How we approach an acquired thrombotic thrombocytopenic purpura patient

Jay S. Raval, Marshall A. Mazepa, Mark E. Brecher, Yara A. Park

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Acquired thrombotic thrombocytopenic purpura (TTP) is a disease characterized by microangiopathic hemolytic anemia and thrombocytopenia, in addition to variable fever and neurologic and renal dysfunction, without an underlying cause. Recent advances in elucidating the pathophysiology of acquired TTP have led to new testing that we have incorporated into our current management of patients with suspected acquired TTP. Despite these developments, much of the treatment for acquired TTP beyond therapeutic plasma exchange (TPE) is based on low-quality evidence. Our group has a sustained interest in studying and optimizing the use of TPE, along with other concurrent therapies, in acquired TTP patients. Described herein is a summary of how our apheresis consult service approaches requests for TPE in patients with suspected acquired TTP.

Original languageEnglish (US)
Pages (from-to)2375-2382
Number of pages8
Issue number10
StatePublished - Oct 1 2014


Dive into the research topics of 'How we approach an acquired thrombotic thrombocytopenic purpura patient'. Together they form a unique fingerprint.

Cite this